-
公开(公告)号：US09029521B2
公开(公告)日：2015-05-12
申请号：US13468730
申请日：2012-05-10
IPC分类号： C07K14/435 , C12N9/12 , C07K14/47 , A61K31/506 , C12N15/113 , C12Q1/48 , C12Q1/68
CPC分类号： C12N15/1137 , A61K31/506 , C07K14/47 , C07K2319/00 , C12N9/1205 , C12N2310/14 , C12Q1/485 , C12Q1/6886
摘要： The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion protein or polynucleotide, a method for screening a therapeutic agent for cancer, and a method for treating cancer that is shown to be positive for the fusion gene. Further, the present invention relates kit, primer set, and probe useful in the detection of cancer that is shown to be positive for the fusion gene.
摘要翻译： 本发明人发现存在于某些癌症患者中的融合基因是癌基因。 本发明涉及作为新型融合蛋白的多肽，编码多肽的多核苷酸，包含多核苷酸的载体，包含载体的转化细胞，检测融合蛋白或多核苷酸的方法，用于筛选治疗剂的方法 癌症和治疗癌症的方法，所述方法显示为融合基因呈阳性。 此外，本发明涉及可用于检测癌症的试剂盒，引物组和探针，其对于融合基因显示为阳性。
-
公开(公告)号：US20130158095A1
公开(公告)日：2013-06-20
申请号：US13468730
申请日：2012-05-10
IPC分类号： C12N9/12 , C12N15/113 , A61K31/506 , C12Q1/68 , C12Q1/48
CPC分类号： C12N15/1137 , A61K31/506 , C07K14/47 , C07K2319/00 , C12N9/1205 , C12N2310/14 , C12Q1/485 , C12Q1/6886
摘要： The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion protein or polynucleotide, a method for screening a therapeutic agent for cancer, and a method for treating cancer that is shown to be positive for the fusion gene. Further, the present invention relates kit, primer set, and probe useful in the detection of cancer that is shown to be positive for the fusion gene.
摘要翻译： 本发明人发现存在于某些癌症患者中的融合基因是癌基因。 本发明涉及作为新型融合蛋白的多肽，编码多肽的多核苷酸，包含多核苷酸的载体，包含载体的转化细胞，检测融合蛋白或多核苷酸的方法，用于筛选治疗剂的方法 癌症和治疗癌症的方法，所述方法显示为融合基因呈阳性。 此外，本发明涉及可用于检测癌症的试剂盒，引物组和探针，其对于融合基因显示为阳性。
-
公开(公告)号：US08197818B2
公开(公告)日：2012-06-12
申请号：US13086245
申请日：2011-04-13
CPC分类号： C12N15/1137 , A61K31/506 , C07K14/47 , C07K2319/00 , C12N9/1205 , C12N2310/14 , C12Q1/485 , C12Q1/6886
摘要： The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion protein or polynucleotide, a method for screening a therapeutic agent for cancer, and a method for treating cancer that is shown to be positive for the fusion gene. Further, the present invention relates kit, primer set, and probe useful in the detection of cancer that is shown to be positive for the fusion gene.
摘要翻译： 本发明人发现存在于某些癌症患者中的融合基因是癌基因。 本发明涉及作为新型融合蛋白的多肽，编码多肽的多核苷酸，包含多核苷酸的载体，包含载体的转化细胞，检测融合蛋白或多核苷酸的方法，用于筛选治疗剂的方法 癌症和治疗癌症的方法，所述方法显示为融合基因呈阳性。 此外，本发明涉及可用于检测癌症的试剂盒，引物组和探针，其对于融合基因显示为阳性。
-
公开(公告)号：US07964710B2
公开(公告)日：2011-06-21
申请号：US12466920
申请日：2009-05-15
CPC分类号： C12N15/1137 , A61K31/506 , C07K14/47 , C07K2319/00 , C12N9/1205 , C12N2310/14 , C12Q1/485 , C12Q1/6886
摘要： The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion protein or polynucleotide, a method for screening a therapeutic agent for cancer, and a method for treating cancer that is shown to be positive for the fusion gene. Further, the present invention relates kit, primer set, and probe useful in the detection of cancer that is shown to be positive for the fusion gene.
摘要翻译： 本发明人发现存在于某些癌症患者中的融合基因是癌基因。 本发明涉及作为新型融合蛋白的多肽，编码多肽的多核苷酸，包含多核苷酸的载体，包含载体的转化细胞，检测融合蛋白或多核苷酸的方法，用于筛选治疗剂的方法 癌症和治疗癌症的方法，所述方法显示为融合基因呈阳性。 此外，本发明涉及可用于检测癌症的试剂盒，引物组和探针，其对于融合基因显示为阳性。
-
公开(公告)号：US20110071146A1
公开(公告)日：2011-03-24
申请号：US12943435
申请日：2010-11-10
申请人： Tatsuya Niimi , Akio Kamikawa , Yasushi Amano , Tomohiko Yamaguchi , Kenichi Suzumura , Kentaro Enjo , Takashi Furutani , Akio Kakefuda , Yutaka Kondoh , Masaaki Hirano
发明人： Tatsuya Niimi , Akio Kamikawa , Yasushi Amano , Tomohiko Yamaguchi , Kenichi Suzumura , Kentaro Enjo , Takashi Furutani , Akio Kakefuda , Yutaka Kondoh , Masaaki Hirano
IPC分类号： A61K31/536 , A61K31/40 , A61K31/415 , A61K31/44 , A61K31/41 , A61K31/4965 , A61K31/505 , A61K31/42 , A61P13/08
CPC分类号： C07D209/08 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D513/04
摘要： To provide a novel and excellent method for treating and/or preventing prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, lung cancer, endometriosis, leiomyoma and the like based on selective inhibitory activity against 17βHSD type 5.It was found that an N-sulfonylindole derivative, where the indole ring is substituted by a carboxy group, a carboxy-substituted lower alkyl group or a carboxy-substituted lower alkenyl group at its carbon atom, has potent selective inhibitory activity against 17βHSD type 5 and may become a therapeutic agent and/or preventive agent for benign prostatic hyperplasia, prostatic cancer and the like without accompanying adverse drug reactions due to a decrease in testosterone, and the present invention has thus been completed.
摘要翻译： 提供治疗和/或预防前列腺癌，良性前列腺增生，痤疮，皮脂溢，多毛症，秃发，脱发，早熟青春期，肾上腺肥大，多囊卵巢综合征，乳腺癌，肺癌，子宫内膜异位症，平滑肌瘤和 基于针对17＆amp; HSD型5的选择性抑制活性的类似物。已经发现，吲哚环被羧基取代的N-磺基吲哚衍生物，羧基取代的低级烷基或羧基取代的低级烯基 在其碳原子上具有对17和HSD 5型的有效的选择性抑制活性，并且可能成为由于睾丸激素降低引起的伴有不良药物反应的良性前列腺增生，前列腺癌等的治疗剂和/或预防剂， 从而完成了本发明。
-
公开(公告)号：US07855225B2
公开(公告)日：2010-12-21
申请号：US12281416
申请日：2007-03-01
申请人： Tatsuya Niimi , Akio Kamikawa , Yasushi Amano , Tomohiko Yamaguchi , Kenichi Suzumura , Kentaro Enjo , Takashi Furutani , Akio Kakefuda , Yutaka Kondoh , Masaaki Hirano
发明人： Tatsuya Niimi , Akio Kamikawa , Yasushi Amano , Tomohiko Yamaguchi , Kenichi Suzumura , Kentaro Enjo , Takashi Furutani , Akio Kakefuda , Yutaka Kondoh , Masaaki Hirano
IPC分类号： C07D209/42 , A61K31/404
CPC分类号： C07D209/08 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D513/04
摘要： To provide a novel and excellent method for treating and/or preventing prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, lung cancer, endometriosis, leiomyoma and the like based on selective inhibitory activity against 17βHSD type 5.It was found that an N-sulfonylindole derivative, where the indole ring is substituted by a carboxy group, a carboxy-substituted lower alkyl group or a carboxy-substituted lower alkenyl group at its carbon atom, has potent selective inhibitory activity against 17βHSD type 5 and may become a therapeutic agent and/or preventive agent for benign prostatic hyperplasia, prostatic cancer and the like without accompanying adverse drug reactions due to a decrease in testosterone, and the present invention has thus been completed.
摘要翻译： 提供治疗和/或预防前列腺癌，良性前列腺增生，痤疮，皮脂溢，多毛症，秃发，脱发，早熟性青春期，肾上腺肥大，多囊卵巢综合征，乳腺癌，肺癌，子宫内膜异位症，平滑肌瘤和 基于针对17＆amp; HSD型5的选择性抑制活性的类似物。已经发现，吲哚环被羧基取代的N-磺基吲哚衍生物，羧基取代的低级烷基或羧基取代的低级烯基 在其碳原子上具有对17和HSD 5型的有效的选择性抑制活性，并且可能成为由于睾丸激素降低引起的伴有不良药物反应的良性前列腺增生，前列腺癌等的治疗剂和/或预防剂， 从而完成了本发明。
-
公开(公告)号：US20100240673A1
公开(公告)日：2010-09-23
申请号：US12466920
申请日：2009-05-15
CPC分类号： C12N15/1137 , A61K31/506 , C07K14/47 , C07K2319/00 , C12N9/1205 , C12N2310/14 , C12Q1/485 , C12Q1/6886
摘要： The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion protein or polynucleotide, a method for screening a therapeutic agent for cancer, and a method for treating cancer that is shown to be positive for the fusion gene. Further, the present invention relates kit, primer set, and probe useful in the detection of cancer that is shown to be positive for the fusion gene.
摘要翻译： 本发明人发现存在于某些癌症患者中的融合基因是癌基因。 本发明涉及作为新型融合蛋白的多肽，编码多肽的多核苷酸，包含多核苷酸的载体，包含载体的转化细胞，检测融合蛋白或多核苷酸的方法，用于筛选治疗剂的方法 癌症和治疗癌症的方法，所述方法显示为融合基因呈阳性。 此外，本发明涉及可用于检测癌症的试剂盒，引物组和探针，其对于融合基因显示为阳性。
-
公开(公告)号：US20100190826A1
公开(公告)日：2010-07-29
申请号：US12670384
申请日：2008-07-23
申请人： Akio Kakefuda , Yutaka Kondoh , Masaaki Hirano , Akio Kamikawa , Kentaro Enjo , Takashi Furutani
发明人： Akio Kakefuda , Yutaka Kondoh , Masaaki Hirano , Akio Kamikawa , Kentaro Enjo , Takashi Furutani
IPC分类号： A61K31/4184 , C07D209/04 , C07D235/18 , C07D403/04 , A61K31/404 , A61K31/454 , A61P35/00 , A61P17/10
CPC分类号： C07D209/08 , C07D209/12 , C07D235/06 , C07D235/08 , C07D235/10 , C07D235/12 , C07D235/18 , C07D235/26 , C07D401/04 , C07D401/06 , C07D405/04
摘要： Provided is a novel and excellent method for treating and/or preventing benign prostatic hyperplasia, prostate cancer, and the like based on selective inhibitory activity against 17βHSD type 5. It was found that an indole or benzimidazole derivative, where a nitrogen atom of the indole ring or benzimidazole ring is substituted with a phenyl group substituted with COOH, has a potent selective inhibitory activity against 17βHSD type 5 and may become an agent for treating and/or an agent for preventing a disease associated with 17βHSD type 5, such as benign prostatic hyperplasia, prostate cancer and the like, without accompanying adverse effects due to a decrease in testosterone; and the present invention has thus been completed.
摘要翻译： 本发明提供了一种用于治疗和/或预防良性前列腺增生症，前列腺癌等的基于17＆amp; HSD型5的选择性抑制活性的新颖且优异的方法。发现吲哚或苯并咪唑衍生物，其中氮 吲哚环或苯并咪唑环被用COOH取代的苯基取代，对17和HSD 5型具有有效的选择性抑制活性，并且可以成为用于治疗和/或用于预防与17型糖尿病相关的疾病的药物 5，如良性前列腺增生，前列腺癌等，不伴随睾丸激素降低引起的不良反应; 从而完成了本发明。
-
公开(公告)号：US20090099193A1
公开(公告)日：2009-04-16
申请号：US12100595
申请日：2008-04-10
CPC分类号： C12N15/1137 , A61K31/506 , C07K14/47 , C07K2319/00 , C12N9/1205 , C12N2310/14 , C12Q1/485 , C12Q1/6886
摘要： The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, and a therapeutic agent for cancer.
摘要翻译： 本发明人发现存在于某些癌症患者中的融合基因是癌基因。 本发明涉及作为新型融合蛋白的多肽，编码多肽的多核苷酸，包含多核苷酸的载体，包含载体的转化细胞和癌症治疗剂。
-
公开(公告)号：US07297698B2
公开(公告)日：2007-11-20
申请号：US10521119
申请日：2003-07-11
申请人： Nobuaki Taniguchi , Masakazu Imamura , Masahiko Hayakawa , Kenichi Kawaguchi , Takenori Kimura , Isao Kinoyama , Hiroyuki Kaizawa , Minoru Okada , Takashi Furutani
发明人： Nobuaki Taniguchi , Masakazu Imamura , Masahiko Hayakawa , Kenichi Kawaguchi , Takenori Kimura , Isao Kinoyama , Hiroyuki Kaizawa , Minoru Okada , Takashi Furutani
IPC分类号： A61K31/4965 , C07D403/00
CPC分类号： C07D213/75 , C07D213/84 , C07D239/42 , C07D295/215
摘要： The present invention relates to a novel N-phenyl-(2R,5S)dimethylpiperazine derivatives useful as antiandrogenic agent which exhibits a sufficient prostate gland reducing effect as compared with conventional compounds and are excellent in oral activity. The compound of the present application is useful in preventing or treating prostate cancer, benign prostatic hyperplasia, and the like. The present invention also provides a novel intermediate useful in producing the compound of the present invention.
摘要翻译： 本发明涉及用作抗雄激素剂的新型N-苯基 - （2R，5S）二甲基哌嗪衍生物，其与常规化合物相比表现出足够的前列腺减少效果，口服活性优异。 本申请的化合物可用于预防或治疗前列腺癌，良性前列腺增生等。 本发明还提供了可用于制备本发明化合物的新型中间体。
-
-
-
-
-
-
-
-
-
搜索结果
39 条记录 (耗时 0.038 秒)
